0.41
+0(+0.00%)
Currency In USD
Address
1455 Adams Drive
Menlo Park, CA 94025
United States of America
Phone
650 446 7888
Website
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
December 15, 2017
| Name | Title | Pay | Year Born |
| Dr. John M. Amatruda M.D., Ph.D. | Co-Founder | 31,500 | 1945 |
| Dr. Nir Yacov Barzilai M.D. | Founder & Member of Scientific Advisory Board | 65,250 | 1956 |
| Dr. Pinchas Cohen Dean, M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 65,250 | 1957 |
| Ms. Jordyn Tarazi | Director of Investor Relations | 0 | N/A |
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.